Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 84.82 3.14% 2.58
ICPT closed up 3.14 percent on Tuesday, June 19, 2018, on 88 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ICPT trend table...

Date Alert Name Type % Chg
Jun 19 Upper Bollinger Band Walk Strength 0.00%
Jun 19 Overbought Stochastic Strength 0.00%
Jun 19 Upper Bollinger Band Touch Strength 0.00%
Jun 18 NR7 Range Contraction 3.14%
Jun 18 Upper Bollinger Band Walk Strength 3.14%
Jun 18 Inside Day Range Contraction 3.14%
Jun 18 Overbought Stochastic Strength 3.14%
Jun 15 Upper Bollinger Band Walk Strength 2.28%
Jun 15 Above Upper BB Strength 2.28%
Jun 15 Overbought Stochastic Strength 2.28%

Older signals for ICPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 135.59
52 Week Low 51.05
Average Volume 636,293
200-Day Moving Average 67.3114
50-Day Moving Average 72.4604
20-Day Moving Average 75.395
10-Day Moving Average 79.134
Average True Range 3.5016
ADX 23.12
+DI 30.72
-DI 9.52
Chandelier Exit (Long, 3 ATRs ) 75.2152
Chandelier Exit (Short, 3 ATRs ) 76.1348
Upper Bollinger Band 85.2162
Lower Bollinger Band 65.5738
Percent B (%b) 0.98
BandWidth 26.052656
MACD Line 3.3694
MACD Signal Line 2.3723
MACD Histogram 0.9971
Fundamentals Value
Market Cap 2.13 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -5.48
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 91.26
Resistance 3 (R3) 90.84 88.28 90.18
Resistance 2 (R2) 88.28 86.64 88.49 89.82
Resistance 1 (R1) 86.55 85.63 87.42 86.97 89.47
Pivot Point 83.99 83.99 84.42 84.20 83.99
Support 1 (S1) 82.26 82.35 83.13 82.68 80.17
Support 2 (S2) 79.70 81.34 79.91 79.82
Support 3 (S3) 77.97 79.70 79.46
Support 4 (S4) 78.39